In ALK fusion-driven NSCLC, patients exposed to earlier-generation ALK inhibitors develop single ALK mutations, including L1196M and G1202R that can be overcome by lorlatinib13,16,18,20,21,37, but the L1196M/G1202R compound mutation causes lorlatinib resistance13,20. Here, ALK is linked to non-small cell lung carcinoma.